Can low iron impair cellular energy production before hemoglobin drops?

Iron’s role in mitochondrial metabolism provides a biologically credible explanation for symptoms that can occur with iron deficiency despite a normal hemoglobin concentration. The core biochemical premise is well established; the timing and clinical magnitude of energy impairment before anemia are supported mainly by cellular and animal data.

Mechanistic evidence

• Iron is an essential constituent of heme and iron–sulfur (Fe–S) cofactors in the electron-transport chain. Heme-containing proteins include complexes II–IV and cytochrome c; Fe–S centers are required in complexes I–III.
• These cofactors transfer electrons from NADH and succinate to oxygen and help generate the proton gradient used for oxidative ATP synthesis. Reduced iron availability can therefore compromise respiratory-complex function, oxygen consumption, and ATP-linked respiration.
• In nonanemic iron-deficient mice, skeletal-muscle complex I activity and endurance declined, particularly in oxidative muscle, while complex IV was unchanged. In iron-depleted human cardiomyocytes, ATP-linked respiration and activity of Fe–S-containing complexes I–III fell and improved after iron repletion.

Clinical relevance

• Bioenergetic impairment can plausibly occur while hemoglobin remains normal, as a parallel consequence of depleted cellular iron rather than a consequence of anemia itself.
• In nonanemic women with low or borderline ferritin, randomized placebo-controlled trials found greater improvement in self-reported fatigue with oral iron than placebo. However, systematic-review evidence has not shown clear improvement in objective physical capacity.
• Normal hemoglobin therefore does not exclude iron deficiency. In adults without inflammation, ferritin <30 μg/L strongly supports deficiency; transferrin saturation can assist interpretation when inflammation may elevate ferritin.

Bottom line

• The claim is substantially supported: iron is indispensable for mitochondrial electron transport, and low iron availability can impair cellular energy production before hemoglobin declines. The strongest direct evidence for this pre-anemia effect is mechanistic, cellular, and animal-based; human clinical evidence currently supports fatigue improvement more clearly than measurable performance or direct mitochondrial outcomes.